Abstract PS1-01-19: Exploratory Study on the Efficacy and Safety of Combined Scalp Cooling and HairRepro MEDIα for Chemotherapy-Induced Alopecia in Japanese Breast Cancer Patients
February 2026
in “
Clinical Cancer Research
”
TLDR The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.
This exploratory study evaluated the efficacy and safety of combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion in 22 Japanese breast cancer patients undergoing adjuvant chemotherapy to prevent and recover from chemotherapy-induced alopecia (CIA). The results showed a 50% success rate in achieving Grade 1 or lower alopecia, with all patients experiencing full scalp hair regrowth by 3 months post-chemotherapy. The combination therapy delayed the onset of alopecia compared to historical data of PAXMAN-only users and demonstrated no adverse events related to HairRepro MEDI α. These findings suggest that the combined treatment may offer enhanced efficacy in CIA management, warranting further randomized trials to confirm these preliminary results.